FDA Okays First Targeted Agent for HER2-Low Breast Cancer FDA Okays First Targeted Agent for HER2-Low Breast Cancer

The targeted therapy led to longer progression-free and overall survival compared with chemotherapy.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news